Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A novel melanocortin fusion protein inhibits fibrinogen oxidation and degradation during trauma-induced coagulopathy

Chang Yeop Han, Xu Wang, Kristyn M. Ringgold, Jennifer C. Bennett, Alexander E. St. John, Ronald Berenson, Susan A. Stern, Nathan J. White

Blood (2023) 142 (8): 724–741.

https://doi.org/10.1182/blood.2022019164

Published: 2023

Includes: Supplemental data

Journal Articles

Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.

Douglas V Faller, MD, PhD, Sajal Ghosh, PhD, Tatyana Feldman, MD, Adam Lerner, MD, Judith Smith, RN, Andre Goy, MD, Ronald Berenson, MD, Susan Perrine, MD

Blood (2009) 114 (22): 4754.

https://doi.org/10.1182/blood.V114.22.4754.4754

Published: 2009

Journal Articles

A Multi-Lineage Oral Hemokine™ HQK-1002 Enhances Neutrophil Recovery in Sub-Lethally Irradiated Mice and in Baboons.

Susan Perrine, MD, Michael Boosalis, PhD, Stanley Kosanke, DVM, Gary White, DVM, Serguei A. Castaneda, MD, Audry Thomson, MS, Hua Cao, PhD, Ray Fei, MD, Ronald Berenson, MD, Douglas Faller, MD, PhD

Blood (2009) 114 (22): 2509.

https://doi.org/10.1182/blood.V114.22.2509.2509

Published: 2009

Journal Articles

HQK-1001 Has Additive HbF-Inducing Activity in Combination with Hydroxyurea and Decitabine.

Susan Perrine, MD, Douglas V. Faller, MD, PhD, Ling Shen, MD, MPH, Michael Boosalis, PhD, Gary White, DVM, Hua Cao, MD, PhD, Ray Fei, MD, Audry Thomson, MS, Ronald Berenson, MD

Blood (2009) 114 (22): 977.

https://doi.org/10.1182/blood.V114.22.977.977

Published: 2009

Journal Articles

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

Susan Perrine, MD, William C Welch, PhD, Jeffrey Keefer, MD, PhD, Robin L Downey, MD, Michael S Boosalis, PhD, Sally Case, RN, Douglas V Faller, MD, PhD, Ronald Berenson, MD

Blood (2008) 112 (11): 130.

https://doi.org/10.1182/blood.V112.11.130.130

Published: 2008

Journal Articles

Multicenter Phase III Trial to Evaluate CD34 + Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma

Blood (1999) 93 (6): 1858–1868.

https://doi.org/10.1182/blood.V93.6.1858.406k06_1858_1868

Published: 1999

Journal Articles

A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose Chemotherapy

Elizabeth J. Shpall, C. Fred LeMaistre, Kent Holland, Edward Ball, Roy B. Jones, Rein Saral, Cindy Jacobs, Shelly Heimfeld, Ronald Berenson, Richard Champlin

Blood (1997) 90 (11): 4313–4320.

https://doi.org/10.1182/blood.V90.11.4313

Published: 1997

NARROW

A novel melanocortin fusion protein inhibits fibrinogen oxidation and degradation during trauma-induced coagulopathy

Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.

A Multi-Lineage Oral Hemokine™ HQK-1002 Enhances Neutrophil Recovery in Sub-Lethally Irradiated Mice and in Baboons.

HQK-1001 Has Additive HbF-Inducing Activity in Combination with Hydroxyurea and Decitabine.

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

Multicenter Phase III Trial to Evaluate CD34 + Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma

A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

A novel melanocortin fusion protein inhibits fibrinogen oxidation and degradation during trauma-induced coagulopathy

Short-Term Exposure to Arginine Butyrate, in Combination with Ganciclovir, Is as Effective as Continuous Exposure for Virus-Targeted Therapy of EBV-Positive Lymphomas.

A Multi-Lineage Oral Hemokine™ HQK-1002 Enhances Neutrophil Recovery in Sub-Lethally Irradiated Mice and in Baboons.

HQK-1001 Has Additive HbF-Inducing Activity in Combination with Hydroxyurea and Decitabine.

Phase 1 Clinical Testing of HQK-1001, a Novel Oral Fetal Globin Gene Inducer

Multicenter Phase III Trial to Evaluate CD34 + Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma

A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only